Iterum Therapeutics plc (ITRM)

IE — Healthcare Sector
Peers: ONTX  ADIL  DFFN  AEZS  TNXP  FBIO  EYEN  OCUP  GRTX  CTXR  JAGX  ACST  IBIO  FWBI  DRMA  REVB  PBLA  CFRX  VRCA  HOTH  VINC 

Automate Your Wheel Strategy on ITRM

With Tiblio's Option Bot, you can configure your own wheel strategy including ITRM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ITRM
  • Rev/Share 0.0
  • Book/Share -0.075
  • PB -12.669
  • Debt/Equity 0.0
  • CurrentRatio 3.7246
  • ROIC -0.5448

 

  • MktCap 38000000.0
  • FreeCF/Share -0.4918
  • PFCF -2.2685
  • PE -1.434
  • Debt/Assets 0.0
  • DivYield 0
  • ROE 3.1064

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Iterum Therapeutics Announces Extension of Term of Promissory Note
ITRM
Published: May 19, 2025 by: GlobeNewsWire
Sentiment: Neutral

DUBLIN and CHICAGO, May 19, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported that Pfizer Inc. (“Pfizer”) has agreed to extend the term for payment of the regulatory milestone payment of $20.0 million until October 25, 2029.

Read More
image for news Iterum Therapeutics Announces Extension of Term of Promissory Note
Iterum Therapeutics plc (ITRM) Q1 2025 Earnings Call Transcript
ITRM
Published: May 13, 2025 by: Seeking Alpha
Sentiment: Neutral

Iterum Therapeutics plc (NASDAQ:ITRM ) Q1 2025 Earnings Conference Call May 13, 2025 8:30 AM ET Company Participants Louise Barrett - SVP, Legal Affairs Corey Fishman - Chief Executive Officer Judy Matthews - Chief Financial Officer Conference Call Participants Matthew Keller - H.C. Wainwright Operator Hello, everyone, and thank you for joining the Iterum Therapeutics plc First Quarter 2025 Earnings and Business Update Call.

Read More
image for news Iterum Therapeutics plc (ITRM) Q1 2025 Earnings Call Transcript
Iterum Therapeutics to Report First Quarter 2025 Financial Results on May 13, 2025
ITRM
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral

DUBLIN, Ireland and CHICAGO, May 06, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its first quarter 2025 financial results before the open of the U.S. financial markets on Tuesday, May 13, 2025. Management will host a conference call at 8:30 a.m.

Read More
image for news Iterum Therapeutics to Report First Quarter 2025 Financial Results on May 13, 2025

About Iterum Therapeutics plc (ITRM)

  • IPO Date 2018-05-25
  • Website https://www.iterumtx.com
  • Industry Biotechnology
  • CEO Mr. Corey N. Fishman
  • Employees 9

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.